Organization: MSBi Valorisation

Mimetogen Pharmaceuticals receives series B financing

Montreal-based Mimetogen Pharmaceuticals has closed a series B financing round to further develop its neurotrophin mimetics to treat dry eye and other degenerative ocular disorders. The financing is provided by Medwell Capital Inc, which is committing up to $2-million in the privately held, clinical-stage spin off from McGill Univ and Lady Davis Institute for Medical…

Allostera raised $17 million in VC financing

Montreal-based Allostera Pharma Inc has raised $17 million in series ‘A’ financing to develop a new class of drugs based on the firm’s proprietary Module X platform technology. So-called allosteramers use modified peptides with highly specific targets that can be developed rapidly and can be taken orally, which may make them more widely accepted than…

MSBi Valorisation introduces new management team

MSBi Valorisation (MSBiV) has selected a new management team to boost its pre-seed and seed-stage commercialization services to its member institutions. The new management team, led by Didier Leconte (president and GM), is introducing a wide range of support and services to members McGill Univ, the Univ of Sherbrooke, Bishop’s Univ and their affiliated research…

MSBi creates subsidiary

MSBi Capital has launched MSBi Valorisation with $4 million in assistance from the regional development agency, Canada Economic Development. MSBi Valorisation will focus on technology projects and early-stage companies and preparing them for further financing….